You are here:

MS research update - Who will go from one episode of symptoms to having definite MS - 12 December 2012

Clinically isolated syndrome (CIS) is the first episode of neurological symptoms which last at least 24 hours. It can be the first indication of what may turn out to be multiple sclerosis. Not everyone who experiences CIS will go on to develop MS and for some people there will be no further symptoms.

MS may be diagnosed using the McDonald criteria which aim to establish whether there has been damage to the central nervous system that is disseminated in time (more than one episode of symptoms, each lasting more than 24 hours, occuring at different dates at least 30 days apart) or disseminated in space (more than one part of the central nervous system has been damaged, usually leading to more than one kind of symptom).

The McDonald criteria use MRI evidence extensively to confirm a diagnosis of MS, together with lumbar puncture evidence in some instances. With these criteria, an MS diagnosis can be made on the basis of one relapse if the MRI evidence of further damage to the nervous system is strong.

How the study was carried out

55 women and 42 men (average age 27) with clinically isolated syndrome in Kuwait were followed every three to six months for two years. A number of factors were recorded: age when symptoms began; gender; the nature of the first symptoms; information from MRI scans of the brain and spine. Each person's case was assessed using the McDonald criteria.

What was found

59 participants with CIS (61%) had a confirmed diagnosis of MS using the McDonald criteria after an average of 10 months (it ranged from six to 14 months). Out of these, the diagnosis of 37 people (38%) satisfied the McDonald criteria based on data from their MRI scans only. The diagnosis of the remaining 22% was based on a second episode of symptoms.

The researchers found that people were more likely to convert from CIS to definite MS if they had a high number of lesions seen by MRI or if symptoms began at an earlier age. The person's gender or the nature of the initial symptoms (such as problems with vision) did not predict whether they would go on to have definite MS.

What does it mean?

Someone who experiences CIS will naturally want to know if they are likely to go on to be diagnosed with MS or whether they are likely to stay symptom free. This can help when deciding whether to begin disease modifying treatments straight away.

This study provides evidence that having first symptoms at a younger age or having evidence of damage to the central nervous system as seen by MRI predict that conversion to MS is more likely.

Alroughani R, Al Hashel J, Lamdhade S, et al.
Predictors of conversion to multiple sclerosis in patients with clinical isolated syndrome using the 2010 revised Mcdonald criteria.
ISRN Neurol. 2012;2012:792192.
abstract

You can read the full text of the article online.

More on CIS and diagnosing MS

More information about clinically isolated syndrome (CIS) and the McDonald criteria is available in the A to Z of MS.

The process of diagnosing MS can take some time and usually involves taking a history and description of the symptoms experienced, doing some neurological tests (often including for vision, balance and reflexes) and having an MRI scan. It may also include a lumbar puncture or evoked potential tests.

Research by topic areas...

Symptoms and symptom management

Thouvenot E, Mura F, De Verdal M, et al.
Ipsilateral uveitis and optic neuritis in multiple sclerosis.
Mult Scler Int. 2012;2012:372361.
abstract

Gervasoni E, Cattaneo D, Montesano A, et al.
Effects of fatigue on balance and mobility in subjects with multiple sclerosis: a brief report.
ISRN Neurol. 2012;2012:316097.
abstract

Lunde HM, Bjorvatn B, Myhr KM, et al.
Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review.
Acta Neurol Scand Suppl. 2013;(196):24-30.
abstract

Disease modifying treatments

Tur C, Tintoré M, Vidal-Jordana A, et al.
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
Mult Scler. 2012 Aug;18(8):1193-6.
abstract

Assessment tools

Ryan JJ, Gontkovsky ST, Kreiner DS, et al.
Wechsler Adult Intelligence Scale-Fourth Edition performance in relapsing-remitting multiple sclerosis.
J Clin Exp Neuropsychol. 2012;34(6):571-9
abstract

Moodie J, Healy BC, Buckle GJ, et al.
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study.
J Neurol Sci. 2012 Apr 15;315(1-2):49-54.
abstract

Fanchamps MH, Gensicke H, Kuhle J, et al.
Screening for balance disorders in mildly affected multiple sclerosis patients.
J Neurol.2012 Jul;259(7):1413-9.
abstract

Causes of MS

Virtanen JO, Jacobson S.
Viruses and multiple sclerosis.
CNS Neurol Disord Drug Targets. 2012 Aug;11(5):528-44.
abstract

Vitamin D

Ho SL, Alappat L, Awad AB.
Vitamin D and multiple sclerosis.
Crit Rev Food Sci Nutr. 2012;52(11):980-7
abstract

Peterlik M.
Vitamin D insufficiency and chronic diseases: hype and reality.
Food Funct. 2012 Aug;3(8):784-94.
abstract

Economics

Bergvall N, Tambour M, Henriksson F, et al.
Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
J Med Econ. 2012 Dec 4. [Epub ahead of print]
abstract

Bandari DS, Sternaman D, Chan T, et al.
Evaluating risks, costs, and benefits of new and emerging therapies to optimize outcomes in multiple sclerosis.
J Manag Care Pharm. 2012 Dec;18(9):1-17.
abstract

Péntek M, Gulácsi L, Rózsa C, et al.
Health status and costs of ambulatory patients with multiple sclerosis in Hungary.
Ideggyogy Sz. 2012 Sep 30;65(9-10):316-24.
abstract

Prognosis

Patrucco L, Rojas JI, Cristiano E.
Assessing the value of spinal cord lesions in predicting development of multiple sclerosis in patients with clinically isolated syndromes.
J Neurol. 2012 Jul;259(7):1317-20.
abstract

Other

Vickers MH.
Antenarratives to inform health care research: exploring workplace illness disclosure for people with multiple sclerosis (MS).
J Health Hum Serv Adm. 2012 Fall;35(2):170-206.
abstract

Year: 2016

December 2016

November 2016

July 2016

May 2016

April 2016

March 2016

February 2016

January 2016

Year: 2015

December 2015

November 2015

October 2015

May 2015

April 2015

March 2015

February 2015

January 2015

Year: 2014

December 2014

November 2014

October 2014

September 2014

August 2014

July 2014

June 2014

May 2014

April 2014

March 2014

February 2014

January 2014

Year: 2013

December 2013

November 2013

October 2013

September 2013

August 2013

July 2013

June 2013

May 2013

April 2013

March 2013

February 2013

January 2013

Year: 2012

December 2012

November 2012

October 2012

September 2012

August 2012

July 2012

June 2012

May 2012

April 2012

March 2012

February 2012

January 2012

Print this page

Rate this page:

Fieldset
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.

Please fill in the fields below if you would like to stay in touch with the MS Trust to help with further testing and feedback on the MS Trust website

Do you have a question about MS? Contact our enquiry team